This website uses cookies
Read our Privacy policy and Terms of use for more information.
CEO @Teknon / Smart people and capable businesses keep losing to louder ones. I fix that. → Helped 300+ leaders Package, Position, & Sell their Expertise | Scaled by AI Systems | HealthTech 🧬
/
Oct 9, 2026
PLUS: MRI2CT's AI generates 3D bone CTs from routine spine MRIs.
Oct 8, 2026
PLUS: How Novartis took oral BTK inhibition into physical friction hives.
Oct 7, 2026
PLUS: How Genmab and AbbVie's bispecific cut lymphoma progression by 51%.
Oct 6, 2026
PLUS: Vaxcyte’s 31-valent vaccine meets pivotal Phase 3 endpoints; Abbott wins approval to show CardioMEMS readings to patients.
Oct 5, 2026
PLUS: Jaypirca gets approved as an Initial Treatment for Certain Adults With CLL/SLL
Oct 2, 2026
PLUS: How pediatric myosin inhibition changes congenital cardiology forever.
Oct 1, 2026
PLUS: The Bedside Diagnostic Wave: Economics of Point-of-Care Neuromonitoring and Cyclical Thrombectomy
Sep 30, 2026
PLUS: The end of 60-minute endoscopic frame scrubbing & ER triage margins
Sep 29, 2026
PLUS: The MCT8 Treatment Boundary: What Emcitate’s Approval Changes and What It Leaves Open
Sep 28, 2026
PLUS: The HealthTech Signal Plus: Stentless Cath Lab Economics & Receptor Subtype Neurology
Sep 26, 2026
PLUS: Inside the Once-Weekly Metabolic Shift & Outpatient Cardiology Economics
Sep 25, 2026
PLUS: Why Early-Line Disease Modification Changes Healthcare Valuation Multiples
Sep 24, 2026
PLUS: Inside the MCED Diagnostic Cascade & Generic Radiopharmaceutical Economics
Sep 23, 2026
PLUS: FDA clears MICSI-PET AI and Ultragenyx wins landmark gene therapy approval
Sep 22, 2026
PLUS: The $10,000 cath lab false alarm calculus, oral SERD companion diagnostic moats, and crossover trial biology.
Sep 21, 2026
PLUS: Why sentence-level provenance is pharma's new RWE moat
Sep 18, 2026
PLUS: Altis Labs $25M for AI endpoints and Sling's $123M oral TED pill
Sep 17, 2026
PLUS: What the De Novo classification means for every hospital's liability exposure
Sep 16, 2026
PLUS: FDA launches Expedited IND Pilot, RegCell's $66M Nobel-backed round, and the end of PMA companion diagnostic barriers.
Sep 15, 2026
PLUS: Implicity's $40M cardiac round, Thyme Care $2B valuation, and why SaaS is pivoting to full-stack care.
Sep 14, 2026
PLUS: Scholar Rock's muscle breakthrough, Forus $3B valuation, and the new theranostic playbook.
Sep 13, 2026
PLUS: 🏥 Inspiren hits $500M valuation to eliminate unwitnessed falls
Sep 11, 2026
PLUS: Frazier adds $1.1B, Implicity raises $40M, and clinical AI gets continuous audits
Sep 10, 2026
PLUS: How AI ultrasound cut DVT diagnosis to 30 minutes at NHS Chelsea
Sep 9, 2026
PLUS: An AI-designed drug reversed aging markers. And Adventist Health unified 27 hospitals on one record.
